Botulinum neurotoxins (BoNTs) are the most toxic substances known to mankind and are the causative agents of the neuroparalytic disease botulism. Their ease of production and extreme toxicity have caused these neurotoxins to be classified as Tier 1 bioterrorist threat agents and have led to a sustained effort to develop countermeasures to treat intoxication in case of a bioterrorist attack. While timely administration of an approved antitoxin is effective in reducing the severity of botulism, reversing intoxication requires different strategies. In the present study, we evaluated ABS 252 and other mercaptoacetamide small molecule active-site inhibitors of BoNT/A light chain using an integrated multi-assay approach. ABS 252 showed inhibitory activity in enzymatic, cell-based and muscle activity assays, and importantly, produced a marked delay in time-to-death in mice. The results suggest that a multi-assay approach is an effective strategy for discovery of potential BoNT therapeutic candidates.
Introduction
Botulinum neurotoxins (BoNTs) have been studied extensively for well over a century (Simpson, 2004 (Simpson, , 2013 Rossetto et al., 2014) . While much knowledge has been gleaned from this effort, the ability to rescue intoxicated hosts from BoNT-mediated paralysis has remained elusive (Cai and Singh, 2007; Seki et al., 2015; Kumaran et al., 2015) . BoNT/A is the most toxic of the seven established serotypes, with BoNT/B,/E and/F also showing lethal effects in humans (Simpson, 2004; Montgomery et al., 2015) . The neurotoxins are comprised of a heavy chain (HC) and a light chain (LC), which after proteolytic processing, are covalently linked by a single interchain disulfide bond (DasGupta and Sugiyama,1972) . The HC is responsible for the binding and internalization of BoNT into motor neuron terminals, while the LC is responsible for the observed neurotoxicity (Bandyopadhyay et al., 1987; Dolly et al., 1990; Colasante et al., 2013 (synaptosome-associated protein of 25 kDa) (Blasi et al., 1993; Schiavo et al., 1994) . SNAP-25 is a critical component of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex that controls release of the neurotransmitter acetylcholine. Since acetylcholine is required for neuromuscular and autonomic function (Wu et al., 2012) , intoxication by BoNT/A leads to flaccid paralysis and autonomic dysfunction. Therapy for botulism relies on antitoxins to neutralize BoNT in circulation, and severe cases require intensive care with artificial ventilation (Cheng et al., 2009; Trott et al., 2009; Yu et al., 2009; Adler et al., 2014) . Currently, only one formulation of antitoxin is licensed for clinical use: a despeciated equine-derived heptavalent botulism antitoxin (BAT ® ) that received FDA approval in 2013 (Hill et al., 2013) . Antitoxins although effective, cannot be relied on as the sole treatment for botulism. In addition to the difficulty and cost of producing and stockpiling large quantities of antitoxin, a sizable percent of the population may show hypersensitivity to the equinederived product (Hibbs et al., 1996) . The greatest shortcoming of antitoxin therapy, however, is that this approach is useful only in neutralizing toxin that remains within the bloodstream (Ravichandran et al., 2006) , not in reversing the consequences of intoxication.
Moreover, although dilute forms of the toxin have been approved for medical and aesthetic use (Münchau and Bhatia, 2000; Shukla and Sharma, 2005) , intoxication can occur even with controlled clinical doses of BoNT (Crowner et al., 2007) . Treatment of BoNT intoxication following a bioterrorist attack, natural outbreak or clinical overdose requires a therapeutic agent that is unconstrained by a limited therapeutic window (Kostrzewa et al., 2015) .
From the time that BoNT was revealed to be a Zn 2þ metalloprotease (Schiavo et al., 1992) , efforts have focused on developing small molecule inhibitors (SMIs) targeting the protease activity of the BoNT LCs (Adler et al., 1998; Anne et al., 2001; Eubanks et al., 2010; Silh ar et al., 2013a; Duplantier et al., 2016; Bremer et al., 2017) . Despite considerable effort, development of suitable drug candidates with significant in vivo efficacy has not been achieved. This is due in part to the size and conformational flexibility of the BoNT active site and to the extensive binding interactions between BoNT/A LC (LC/A) and SNAP-25 (Chen et al., 2007; Bremer et al., 2017) . Thus, crystal structure data suggest that the active site of LC/A has a great deal of conformational flexibility, making the design of highly potent SMI inhibitors challenging (Silvaggi et al., 2007; Kumaran et al., 2015; Harrell et al., 2017) . Further complicating a small molecule approach is the presence of ancillary binding sites (exosites) that contribute to the tight binding of SNAP-25 to LC/A (Chen et al., 2007; Xue et al., 2014) . The enzyme-substrate interface that encompasses the active site plus a-and b-exosites has been determined to be ca. 4840 Å 2 (Breidenbach and Brunger, 2004) , an area that would require the cooperative action of multiple inhibitors. An examination of some known active-site inhibitors led to the suggestion of a three-zone pharmacophore model as optimal for inhibitor-LC binding (Hermone et al., 2008) . However, since the substrate binding cleft of LC/A is unusually large, inhibitors with surface areas >200 Å 2 may be required for effective interaction with the active site cavity (Segelke et al., 2004) . This is clearly beyond the purview of a typical SMI (Pang et al., 2009; Kumaran et al., 2015; Harrell et al., 2017) . In this study, we report on the efficacy of the mercaptoacetamide inhibitor ABS 252 in enzymatic and biological assays and assess its ability to extend survival of mice in vivo. In addition, we examine the complex between LC/A and related mercaptoacetamides ABS 143, ABS 367 and ABS 384 (Fig. 1 ) by Xray crystallography to elucidate their interactions with the active site of LC/A. ABS 252 was found to be effective in all assays of BoNT action and produced a significant delay in time-to-death (TTD) when administered to mice challenged with BoNT/A in vivo.
Materials and methods

Chemistry
The rationale and design strategy for the ABS compounds and their synthetic routes have been reported elsewhere (Moe et al., 2009) . For animal protection experiments, the compounds were recrystallized from warm toluene at least 3 times, and each compound was >99% pure with no single impurity accounting for >0.25% based on NMR and HPLC spectra. Unless stated otherwise, stock solutions of ABS compounds were prepared in dimethyl sulfoxide (DMSO) and contained 10 mM inhibitor plus 20 mM tris(2-carboxyethyl)phosphine (TCEP) (ThermoFisher Scientific, Waltham, MA, USA); the latter served to protect the sulfhydryl warhead from undergoing spontaneous oxidation (Winther and Thorpe, 2014) . Since ABS compounds have limited aqueous solubility (Moe et al., 2009 ), preparation of working solutions was made by slow addition (30 s) of DMSO stocks into stirred aqueous solutions at 37 C.
BoNT/A holotoxins with specific toxicity of 2.7 Â 10 8 mouse intraperitoneal (i.p.) LD50 units (U) per mg were obtained from Metabiologics, Inc. (Madison, WI, USA). BoNTs were received in phosphate-buffered saline (PBS; pH 7.0) at a concentration of 6.66 mM. Stock solution was diluted to 100 nM with 0.9% saline containing 0.1% gelatin, aliquoted in single use vials and stored frozen at À20 C.
X-ray structure determination
BoNT/A-LC was expressed in E. coli as a C-terminal truncation mutant (residues 1e425) with an N-terminal His 6 -tag and thrombin cleavage site and purified as described (Silvaggi et al., 2007) . Purified BoNT/A LC425 was crystallized by mixing equal volumes of protein solution (10e12 mg/ml LC425, 50 mM Na 2 HPO 4 , 2 mM EDTA, pH 6.5) and crystallization buffer (10e15% polyethylene glycol [PEG] 2000 monomethyl ester, 0.2e0.3 M K 2 HPO 4 , 0.1 M D,L-malic acid pH 7.0) in the hanging-drop geometry. Clusters of needle and plate-shaped crystals appeared in 2e4 days, reaching a maximum size of 0.2 Â 0.4 mm after 7 days. Crystal morphology was improved by microseeding. Crystal structures of the enzymeinhibitor complexes were obtained by soaking the largest, thickest plates available in solution containing 25% PEG 2000 monomethyl ester, 0.3 M K 2 HPO 4 , 0.1 M D,L-malic acid, 5 mM Zn(NO 3 ) 2 , 5 mM TCEP, 2.5% DMSO, and 2.5 mM inhibitor (ABS 143, ABS 252, ABS 367 or ABS 384). Data for the LC/A:ABS 143 complex were collected on a Rigaku Rotaflex RU-H X-ray diffractometer equipped with osmic mirrors and an R-AXIS IVþþ image plate detector located at Boston University School of Medicine.
Data for the LC/A:ABS 367 and LC/A:ABS 384 complexes were collected at Beamline X29 of the National Synchrotron Light Source, Brookhaven National Laboratory. The structures were determined by molecular replacement using the high-resolution unliganded structure (PDB ID: 3BON) (Silvaggi et al., 2008) as the search model, with waters, Zn 2þ and flexible loops (residues 245e258 and 367e373) removed. The resulting models were refined in phenix refine from the PHENIX suite (Adams et al., 2002) with riding hydrogen atoms (without contribution to F calc ) and TLS (translation/ libration/screw) using groups suggested by TLSMD (TLS motion determination) analysis (Painter and Merritt, 2006 ) (3 groups for chain A and 5 for chain B). After rebuilding parts of the protein model and adding ordered solvent molecules, the inhibitor molecules were modeled into unambiguous difference electron density (contoured at 2.5e3.0s). The quality of the final models was confirmed by MolProbity (Davis et al., 2004 (Ruge et al., 2011) .
2.4. Primary rat cerebellar neuron assay 2.4.1. Culture conditions Neuronal granule cells from pooled cerebella of either 7-or 8-day-old Sprague-Dawley rats (SNAP-25 cleavage assay) or 5-to 7-day-old CD-1 mice (aspartate release assay) were harvested by methods previously described (Skaper et al., 1979) . Cells were cultured in DMEM/F-12 media (Gibco-Invitrogen, Carlsbad, CA, USA) containing 50 U/ml penicillin, 50 mg/ml streptomycin, 10% fetal bovine serum and N2 supplement. Cells were seeded onto poly-L-lysine-coated 24-well plates at a density of 1 Â 10 5 cells per well and cultured in a humidified atmosphere of 93% air/7% CO 2 at 37 C. After 24 h, 10 mM cytosine arabinoside (Sigma-Aldrich, St.
Louis, MO, USA) was added to inhibit the replication of nonneuronal cells. The media was replaced by 75% after 24 h, and completely each week thereafter. 
Cell-based protection studies
Primary cerebellar cells were used 8e30 days post-seeding. Two strategies were used to determine efficacy of ABS 252 against BoNT/ A: 1) ABS 252 was added to cells followed immediately by 500 pM BoNT/A, and cells were assayed for SNAP-25 cleavage 4 h later; 2) cells were exposed to 50 pM BoNT/A for 30 min, washed with PBS to remove unbound neurotoxin, cultured overnight in medium containing ABS 252 and assayed for SNAP-25 cleavage.
To determine the degree of protection of SNAP-25 afforded by ABS 252, cells were washed with PBS, harvested into pre-weighed Eppendorf screw cap vials and pelleted by centrifugation. Cells were lysed by M-PER™ (Mammalian Protein Extraction Reagent; ThermoFisher), solubilized in SDS-PAGE sample buffer and boiled for 10 min prior to immunoblotting.
SNAP-25 immunoblot analysis
Aliquots of primary neuronal extract were resolved by SDS-PAGE on 12% polyacrylamide gels, and proteins were transferred to polyvinylidene fluoride membranes (Millipore Corp., Bedford, MA, USA). The membrane was blocked with 5% nonfat dry milk in TBST buffer (10 mM Tris, 150 mM NaCl, 0.1% Tween 20) for 30 min at room temperature and probed with rabbit anti-SNAP-25 antibody (1:5000, Sigma-Aldrich) in TBST by gentle rocking for at least 1 h at room temperature. The secondary antibody incubation was for 1 h with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:50,000). Blots were washed and developed using enhanced chemiluminescence (GE Healthcare Life Sciences, Marlborough, MA, USA). Band densities for intact and 197-mer truncated SNAP-25 were normalized, and the relative intensity was determined by scanning densitometry.
[ 3 H]D-aspartate release assay
Mouse primary cerebellar neuronal cells were used 10e15 days post-seeding. Cells were pretreated with 40, 50 or 60 mM ABS 252 for 30 min. BoNT/A (50 pM) was then added to the media, and cells were incubated overnight. Cells were washed with PBS (3-times) and incubated at 37 C with 0.2 mCi/ml K-R-g medium containing 25 mM KCl was subsequently added for determination of depolarization-dependent release of
aspartate. Aliquots of K-R-g media were removed at 3-min intervals over 21 min and analyzed for radioactivity to obtain the time course for evoked release. Finally, the radiolabel remaining in the cells was determined by scraping the cell monolayer in 1 ml of scintillation cocktail with 10% bleach. Cells were incubated with this mixture for 10 min to inactivate BoNT/A prior to isotope counting.
aspartate released in the presence of 25 mM KCl was calculated as a percentage of total radioactivity: (dpm released divided by total dpm) minus baseline.
Hemidiaphragm muscle tension assay
Experiments were performed on hemidiaphragm muscles dissected from male CD-1 mice (20e25 g). Mice were housed in Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facilities with food and water available ad libitum as described previously . To obtain isolated muscle preparations, the animals were euthanized by an overdose of isoflurane and decapitated. Hemidiaphragms with attached phrenic nerves were dissected, mounted in temperature-controlled tissue baths and immersed in Tyrode's solution (Sigma-Aldrich) at 37 C. The solution was bubbled with a gas mixture of 95% O 2 /5% CO 2 and had a pH of 7.3. The phrenic nerve was stimulated continually at 0.03 Hz with 0.2 msec supramaximal (6 V) pulses. Muscle twitches were measured with Grass FT03 isometric force displacement transducers (Astro-Med, Inc., West Warwick, RI, USA), digitized and analyzed off-line with pClamp software (Molecular Devices, Sunnyvale, CA, USA). Resting tensions were maintained at 1.0 g to obtain optimal nerve-evoked tensions.
Because no SMI has shown efficacy as a posttreatment drug in BoNT-intoxicated nerve-muscle preparations, ABS 252 was evaluated as a pretreatment. Accordingly, muscles were pretreated with ABS 252 (10 or 100 mM) for 30 min prior to challenge with BoNT/A (5 pM), and twitch tensions were recorded until they fell by ! 50%. Control hemidiaphragm muscles were pretreated with vehicle used for dissolving 100 mM ABS 252 (1% DMSO plus 200 mM TCEP) for30 min, exposed to 5 pM BoNT/A, and monitored concurrently for changes in twitch tension. 2.6. In situ contractions in rat extensor digitorum longus (EDL) muscle
In situ EDL muscle tension measurements were performed on male Sprague Dawley Crl:CD (SD)IGS BR rats (300e350 g) from Charles River housed under an approved AAALAC International program . Local intramuscular (i.m.) injections were performed under isoflurane-oxygen anesthesia (3% isoflurane for induction, 2% for maintenance). After determining adequacy of anesthesia, a small incision was made in the skin on the dorsal surface of the ankle region over the left EDL muscle to allow for injections under direct visual guidance. ABS 252 (10 mM) and TCEP (20 mM) were dissolved in a 1:1 mixture of DMSO:PBS (v/v). TCEP was neutralized to pH 7.4 with NaOH to prevent muscle necrosis at the injection site and was prepared immediately before use for maximal stability (Zhao et al., 2013) .
In groups designated as 3, 5, 7 & 8 in Fig. 6 , 30 ml of ABS-252 was injected i.m. into the hindlimb between the anterior tibialis and EDL muscles using a 26 gauge needle attached to a Hamilton syringe.
Groups 2, 4 & 6 were injected in a similar fashion with a 30 ml solution of 20 mM TCEP dissolved in 1:1 DMSO:PBS (vehicle for ABS 252). PBS was included to minimize local toxic action of neat DMSO (Gad et al., 2006) .
Injections were made near the point of insertion of the peroneal nerve to the EDL muscle to optimize drug delivery to presynaptic terminals. ABS 252 and vehicle administration were followed 1 h later with an injection of 4 U of BoNT/A in a volume of 15 ml, after which the skin incision was closed with Vetbond™ surgical glue (Santa Cruz Biotechnology, Dallas, TX, USA). Right EDL muscles received either no treatment (Group 1), or were pretreated with ABS 252 followed 1 h later by a 15 ml injection of 0.9% saline containing 0.1% gelatin (vehicle for BoNT/A) (Group 8).
To prepare rats for measurement of tension, animals were anesthetized with an isoflurane-oxygen mixture. The peroneal nerve was isolated, and the tendon of the EDL was freed at its distal insertion. The rat was placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) with knee and ankle immobilized. Surgical areas were covered with mineral oil to prevent tissues from drying, and body temperature was maintained by use of a thermostatically controlled heating pad.
Tension measurements were performed at 12, 24 or 48 h, as described earlier (Adler et al., 2001) . The distal tendon of the EDL was attached to a Grass FT03 isometric force displacement transducer (Astro-Med, Inc., West Warwick, RI, USA), and the peroneal nerve was stimulated at 6.5 V for 0.2 msec via a bipolar stainless steel electrode using a Grass S88 stimulator (Astro-Med). Resting tensions were maintained at 5 g, and muscles were allowed to equilibrate for 15 min prior to recording. Tension measurements were performed in duplicate and averaged. Outputs from the transducers were amplified, digitized and analyzed using pClamp software (Molecular Devices). At the end of the recordings, rats were euthanized with Fatal-Plus™ without regaining consciousness (Vortech Pharmaceuticals, Dearborn, MI, USA).
In silico modeling
In silico modeling was used to obtain information about the pharmaceutical properties of ABS 252, such as aqueous solubility, logP (1-octanol/water partition coefficient), polar surface area, molar refractivity and plasma protein binding. The calculations were performed using programs from the Biotechnology High Performance Computing Software Applications Institute (BHSAI) (http://bhsai.org/) and Chem3D Pro (CambridgeSoft Corporation Software).
Effect of ABS 252 on BoNT/A-mediated time-to-death (TTD)
Protection studies were carried out on CD-1 mice at the University of Wisconsin Food Research Institute. ABS 252 was dissolved in 100% DMSO at 20 mg/ml and diluted 1:1 (v/v) in PBS. Compound solubility was marginal under these conditions; however, higher concentrations of DMSO were not well tolerated by the mice. To minimize precipitation of test compound, only enough ABS 252 was prepared to inject 5e7 mice, after which the solution was discarded and more compound was prepared for the next group of animals.
Mice were assigned randomly to vehicle or experimental groups. For drug or vehicle administration, animals were briefly restrained, and 0.1 ml of ABS 252 (1 mg) or vehicle (1:1 DMSO:PBS) was administered intravenously (i.v.) into the left lateral tail vein. After 5 min, mice were challenged by i.p. injection (0.5 ml) of 10 U of BoNT/A.
Data analysis
Data analysis was performed by one-way ANOVA followed by Bonferroni's post hoc tests except for the TTD studies (Table 4) , where data analysis was performed using the Student's t-test (GraphPad Prism). Significance was defined as P 0.05.
Results
X-ray crystallography
X-ray crystal structures of the complexes between the LC/A and ABS 252, as well as the analogs ABS 143, ABS 367 and ABS 384, were determined to elucidate the binding mode of this class of compounds, and to identify parts of the scaffold that might be modified to improve binding and/or inhibitory activity. Since the chemical structures of ABS 252 and ABS 143 are similar (p-fluoro and pchloro, respectively; Fig. 1) , and their complexes with LC/A were essentially identical, we only report on the LC/A:ABS 143 complex here because its crystal structure was of superior quality. As expected from the structures of complexes with other metalchelating SMIs of LC/A (Silvaggi et al., 2007) , these inhibitors bind in the protease active site, primarily through interaction with the catalytic Zn 2þ (Fig. 2) . The sulfur of ABS 143 directly chelates the Zn 2þ and replaces the Zn 2þ -bound water molecule that is required for catalysis of SNAP-25. The monodentate (2.5 Å) interaction between the inhibitor sulfur and Zn 2þ has a geometry typical of Zn 2þ -sulfur interactions (Chakrabarti, 1989) . Thus, like almost all small-molecule and peptidic LC/A inhibitors studied to date, ABS 143 (and by extension ABS 252) and its analogs act by (1) competing with SNAP-25 for access to the active site and (2) disabling the catalytic center by displacing the nucleophilic water molecule from the Zn 2þ coordination sphere. ABS 143/252 makes additional, specific interactions with the LC/A active site. These can be divided into two groups that localize to two distinct regions of the scaffold. The first group consists of three hydrogen bonds between the mercaptoacetamide and pyrazole nitrogens with the backbone of a b-strand that forms one wall of the catalytic site (residues I161-F163, Fig. 2A and B) . The second group consists entirely of hydrophobic contacts between the substituted phenyl ring and a hydrophobic pocket formed by residues V70, I161, F194, F369 and V373. Notably, these same residues (with the exception of F369) form part of the S1 0 subsite that binds the P1 0 Arg of SNAP-25. Specificity is derived from the combination of all three sets of interactions between inhibitor and LC: Zn 2þ coordination, hydrogen bonding (pyrazole moiety), and hydrophobic interactions (phenyl ring).
While the enzyme active site is highly dynamic and accommodates a wide variety of substrate analogs and inhibitors (Park et al., 2006; Burnett et al., 2007; Silvaggi et al., 2007) , there are tight constraints on the distance between the Zn 2þ -chelating group (the warhead) and the hydrophobic pocket, as well as on the size of the pocket. Thus, structure-activity relationship (SAR) studies and existing structural data show that analogs of ABS 143/252 with large substituents at the para position of the phenyl ring are weak inhibitors of the LC/A, because the hydrophobic pocket, though flexible, cannot accommodate groups bulkier than a single atom. In the structures of the ABS 143 and ABS 252 complexes with LC/ A, a water molecule remains bound to R363 approximately 5.5 Å from the pyrazole rings of the bound inhibitors. To evaluate the possibility of adding functionality to the pyrazole ring by displacing this water molecule and making an additional interaction with R363, we determined the structure of LC/A with ABS 367 in the active site (Fig. 2C and D) . This compound has a methyl group at C4 of the pyrazole ring. Given the amount of space around this atom in Fig. 2 . Stereo (A) and schematic (B) views of the active site in the LC/A:ABS 143 complex. In the stereoview, the inhibitor is rendered with orange carbon atoms, LC/A is depicted in grey and Zn 2þ is shown as a metallic silver sphere. The 2jF o j-jF c j electron density contoured at 1.0s is shown as magenta mesh for the inhibitor and 370 loop. The simulated annealing omit electron density map, also contoured at 1.0s, is shown as green mesh for the inhibitor. In the schematic, interactions are labeled with the distance in Å and are colored green for hydrogen bonds and metal ligands and yellow for hydrophobic interactions. Lightly dotted grey lines are used for reference and do not indicate formal interactions. Panels C and D show the same pair of diagrams for the LC/A:ABS 367 structure, and panels E and F show corresponding views for the LC/A:ABS 384 structure. Panels A, C and E were rendered using the POVScript þ modification of MOLSCRIPT and POVRay (Kraulis, 1991; Fenn et al., 2003) .
the LC/A:ABS 143 complex structure, the addition caused a surprising alteration in the binding mode of ABS 367. The mercaptoacetamide sulfur atom still chelates Zn 2þ , but the presence of the methyl group on the pyrazole ring causes it to twist in the active site by~65 relative to the LC/A:ABS 143 structure.
This twist does not prevent the mercaptoacetamide and pyrazole nitrogens from making the same set of hydrogen bonds observed in the LC/A:ABS 143 complex; however, their geometry is somewhat distorted. As a result of the pyrazole twist, the phenyl ring is buried deeper in the active site and occupies a new pocket formed by F163, T193, F194, T215 and T220. R363 is approximately 4.0 Å from the edge of the phenyl ring of ABS 367; thus the Arg moiety encloses the pocket but does not make any direct interactions with the inhibitor. The pyrazole methyl group of ABS 367 is directed toward a sizable pocket that may, in future designs, accommodate additional functionalities at this position. The R363-bound solvent molecule is still present in the LC/A:ABS 367 complex approximately 3.5 Å from the pyrazole methyl group. It is possible that the scaffold might be modified to (1) more fully occupy this space and (2) make direct interactions with R363. Thus, it may be possible to substantially improve the interactions between ABS 367 and active site residues. This assertion is supported by the structure of LC/A with the 4-phenylpyrazole inhibitor ABS 384 ( Fig. 2E and F) . ABS 384 binds with the pyrazole ring at approximately the same angle as ABS 367 but is forced slightly closer to the wall of the active site (residues I161-F163). The phenyl ring is bound in a pocket defined by H223, E224, R363, E351, F369 and T220. In the LC/A:ABS 384 complex, R363 is in a different conformation from that in the ABS 143 structure, leading to displacement of the water molecule that was retained in the ABS 143 and ABS 367 complexes. The ABS scaffold is well suited for design of inhibitor candidates that can interact with diverse active site moieties of LC/A.
Effect of ABS 252 and ABS 143 on BoNT/A LC enzymatic activity
ABS 252 and ABS 143 were tested in a FRET assay with the commercially available reporter BoTest ® A/E and either truncated LC/A 425 or full-length LC/A 448 ( Table 2 ). The former was used since it is a crystallizable form of the LC, and the latter, because its sensitivity to inhibitors resembles that of BoNT/A holotoxin (Kumaran et al., 2015) . ABS 252 and ABS 143 were found to be approximately equipotent in inhibiting the protease activity of each respective LC/A, as expected from their structural similarity (Table 2) . Moreover, both compounds showed a higher affinity for the truncated LC/A 425 compared to the full-length LC/A 448. Similar results were obtained when ABS 252 was applied to primary neurons after intoxication. As shown in Fig. 3B , concentrations of !10 mM ABS 252 antagonized BoNT/A-mediatedSNAP-25 cleavage in neurons that had been exposed to 50 pM BoNT/A for 30 min and then washed before ABS 252 was added. The potency of ABS 252 was consistently greater in the post-intoxication assay, possibly due to the lower toxin concentration used.
Efficacy of ABS
Transmitter release assay
To establish that ABS 252 was able to counteract the inhibitory action of BoNT/A on transmitter release, we employed an 3 [H]Daspartate release assay in primary mouse cerebellar cultures. As shown in Fig. 4 , inhibition of aspartate release by BoNT/A was (Fig. 4) .
Effect of ABS 252 on mouse hemidiaphragm nerve-muscle preparations
Twitch tensions in control mouse diaphragm muscles ranged from 2.6 to 5.2 g (mean ± SEM ¼ 3.4 ± 0.24 g, n ¼ 16) and remained stable for at least 8 h of continuous recording. Addition of 5 pM BoNT/A led to a gradual decline of tension after a 45e60 min latency (Fig. 5A) , culminating in near complete muscle paralysis within 3 h of addition: half-time ¼ 94.8 ± 6.7 min, n ¼ 8 (Fig. 5B) (1) .
The ability of ABS 252 to protect hemidiaphragms from the paralytic action of BoNT/A was determined by pretreating muscles with 10 or 100 mM ABS 252 for 30 min followed by challenge with 5 pM BoNT/A. As shown in Fig. 5B , 10 mM ABS 252 was unable to ameliorate the paralytic action of BoNT/A (3). However, raising the concentration of ABS 252 to 100 mM caused a prolongation of the half-paralysis time to 139.3 ± 10.8 min (4), which was statistically significant (P < 0.001). The vehicle for this concentration of ABS 252 (1% DMSO plus 200 mM TCEP) had no effect on muscle tension under the present experimental conditions (data not shown) and did not alter the inhibitory action of BoNT/A (2) (Fig. 5B ).
Higher concentrations of ABS 252 were not examined in this assay due to problems with solubility of the inhibitor in Tyrode's solution. In addition, DMSO concentrations above 1% often produced spontaneous muscle fasciculation's which were generally followed by a sustained reduction of twitch tension.
Effect of ABS 252 on in situ tensions in rat EDL muscle
Since isolated nerve-muscle preparations have limited viability following excision, they require high concentrations of BoNT/A to allow evaluation of candidate therapeutic agents. Thus, it is not possible to determine whether the action of ABS 252 can be sustained over time in excised hemidiaphragm muscle. However, nerve-muscle preparations in which BoNT is injected locally (to avoid systemic toxicity), and in which tensions are recorded in situ, are better suited to answer this question. Accordingly, ABS-252 was evaluated in rat EDL muscle in situ. EDL muscles were injected locally with 30 ml of a 1:1 DMSO/PBS solution containing 10 mM ABS 252 and 20 mM TCEP 1 h before local injection of 4 U of BoNT/A (15 ml). Other EDL muscles were untreated (1), or served to control for possible injection-induced muscle alterations or for potential pharmacological action of the vehicles used for preparation of ABS-252 or BoNT/A solutions. Muscle tensions in response to peroneal nerve stimulation were determined in situ 12, 24 and 48 h after pretreatment (Adler et al., 1996 (Adler et al., , 2001 . As shown in Fig. 6 , a local injection of BoNT/A (4 U) produced a marked decline of nerveevoked contraction in EDL muscle. By 12 h after injection of BoNT/A, tensions were reduced to 50.7 ± 5.1% of control (2). Tensions continued to decline, reaching 8.9 ± 2.0% (4) and 4.3 ± 2.8% (6) of control, respectively, at 24 and 48 h after exposure to BoNT/A. The paralytic action of BoNT/A was antagonized by ABS 252, which was especially pronounced at the earliest time point. Thus, muscles injected locally with ABS 252 1 h before BoNT/A exhibited tensions of 86.4 ± 10.4% of control after a 12-h exposure to 4 U of BoNT (3). However, by 24 h, tensions in the ABS 252-pretreated muscle were reduced to 37.9 ± 5.4% of control (5), and by 48 h (7), tensions reached levels similar to those observed in muscles exposed to BoNT/A in the absence of ABS 252 (6). As expected, muscles pretreated with ABS 252 and challenged 1-h later with BoNT/A vehicle (0.9% saline containing 0.1% gelatin) showed no decrement in tension (8). The concentration of ABS 252 used for local injections were constrained by the need to maintain solubility of both ABS 252 and TCEP in the vehicle used; the relatively low volume of 30 ml was selected to avoid necrotic lesions of the EDL and surrounding muscles from the local i.m. injection (Treadwell, 2003) .
ABS 252 in silico predictions
Because of their extremely high potency, extraordinary persistence and intracellular localization, few candidate BoNT inhibitors have been able to protect animals from the lethal actions of the neurotoxin. However, based on the efficacy of ABS 252 in primary neurons and in muscle preparations, it was of interest to examine the inhibitor for possible in vivo efficacy. Since neither pharmacokinetic nor ADME (absorption, distribution, metabolism and excretion) data exist for this compound, we performed in silico modeling to obtain estimates of pharmaceutical properties relevant to its suitability as an in vivo drug candidate. The results are summarized in Table 3 .
As shown in Table 3 , the aqueous solubility and plasma protein binding of ABS 252 was predicted to be 251 mM and 64%, respectively, making ABS 252 a reasonable candidate for studies of in vivo efficacy against BoNT/A intoxication. The in silico results suggest that with a sufficiently high dose, it may be possible for ABS 252 to reach a free plasma concentration of 90 mM (251 mM x 0.36), which is in the range found effective in primary cerebellar cells (Figs. 3 and 4 ) and in isolated diaphragm preparations (Fig. 5) . In addition, the absence of a formal charge at physiological pH (Table 3) would enable ABS 252 to penetrate biological membranes and allow it to reach the LC/A in the nerve terminal cytosol. ABS-252 has other desirable attributes for "drug-likeness" such as a polar surface area 140 A 2 , a molar refractivity 40e130 cm 3 /mol) and 10 rotatable bonds. ABS 252 also conforms to Lipinski's rule of five: logP ( 5) hydrogen bond donors ( 5), hydrogen bond acceptors ( 10) and molecular weight 500 Da (Leeson, 2012) .
Effect of ABS 252 on survival times
Although ABS 252 did not protect animals from lethality, it was able to delay the TTD in BoNT/A-intoxicated mice. As shown in Table 4 , ABS 252-pretreated animals survived challenge by 10 U of BoNT/A considerably longer than did control animals. The low aqueous solubility of ABS 252 precluded administering higher doses of drug; however, even with this limitation, ABS 252 showed a significant ability to delay the lethal actions of the neurotoxin (Table 4) . Interestingly, as indicated by the difference in the TTD ratio between group A and B, administration of two doses of ABS 252 appeared to reduce the efficacy of the inhibitor, suggesting that the dose and/or schedule of ABS 252 were not optimal. The reduced efficacy of the two-dose regimen may be due to toxicity of ABS 252 or possibly of DMSO. Further, in experiments where ABS 252 was initially given i.p. followed by a second i.p. dose 1-h later, no protection was observed (data not shown), implying that the more rapid i.v. route may be required for protecting animals against a 10 U challenge of BoNT/A. In addition, the i.p. route may have reduced (8) were recorded at 12, 24 and 48 h after toxin injection (n ¼ 4 at each time point) and pooled. Symbols represent the mean ± SEM of data from 8 to 12 EDL muscles per condition. **Differs significantly from tension recorded in control (1) or ABS 252 pretreated muscle (8): P < 0.001;ˆdiffers significantly from tensions recorded in BoNT/A-injected muscles at 12 h: P < 0.05; #differs significantly from tensions in BoNT/A-injected muscles at 24 h: P < 0.05. the bioavailability of ABS 252 due to possible first pass metabolism.
Discussion
In spite of the intense search for active site inhibitors of BoNT, especially of serotype A, development of SMIs targeted against the LC protease activity of the BoNTs has proven difficult. Complicating discovery efforts are findings that potency against the isolated LC depends on factors such as C-terminal truncation of the LC and the length of the substrate used in enzymatic assays (Baldwin et al., 2004) . A similar observation was recently reported by Kumaran et al. (2015) . Interestingly, their cyclic peptide inhibitor showed a higher potency against full-length LC/A relative to the more commonly used truncated forms (1e425 aa or 1e429 aa). In the current study, ABS compounds were found to be more potent in inhibiting truncated LC/A 425 by a factor of 5.3 for ABS 252 and 7.8 for ABS 143 (Table 2 ). This is in accord with the general preference of SMIs for inhibiting truncated LCs. Silh ar et al. (2013b) proposed that the additional 23 C-terminal residues in LC/A 448 increases the conformational flexibility of the active site, which reduces the binding affinity for SMIs. Although full-length LC/A 448 is clearly the more relevant target for BoNT/A inhibitor studies, it is less often used since the recombinant enzyme in solution has a tendency to form dimers and to undergo autocatalysis ( Silh ar et al., 2013b; Mizanur et al., 2013) .
In a study using peptide-like inhibitors, Zuniga et al. (2010) noted that their model of a pseudo-peptide bound to LC/A could not account for the observed SAR seen in enzyme assays, suggesting that the model for the LC/A developed from the crystal structure may not represent the physiologically relevant enzyme conformation with respect to inhibitor binding modes. In addition, Pang et al. (2009) were unable to improve on the potency of their lead compound based on the model they derived, while Roxas-Duncan et al. (2009) reported on the computer-aided development of an inhibitor that shows low micromolar activity against the isolated enzyme and that, surprisingly, was found to have even greater cellular potency with an EC 50 of 500 nM. ABS 252 also exhibited only modest potency in the cell-free FRET assay (Table 2 ), but relatively high activity in the more relevant cell-based (Figs. 3 and 4) and nerve-muscle assays (Figs. 5 and 6) .
To rationalize the observed difficulties in developing SMIs against BoNT/A, we suggest that LC/A within the cell may have significant structural differences relative to the forms of the enzyme used in cell-free activity assays. Consequently, the enzyme inhibition and crystallography data alone may not be capable of providing a clear pathway for the development of an effective SMI therapeutic. Apparently, there are enough differences between the overall threedimensional conformation of the endogenous enzyme relative to the recombinant LCs that a classical developmental approach may not work. Whether this phenomenon is related to the endogenous enzyme being membrane-bound (Shoemaker and Oyler, 2013) or to post-translational modifications of the LC by host mechanisms (Ferrer-Montiel et al., 1996) remains to be established. However, caution is warranted when trying to draw too detailed of a conclusion from the SAR. The present study reinforces the idea that an integrated approach to the development of inhibitors for the clostridial neurotoxins is necessary (Boldt et al., 2006; Bremer et al., 2017) . Efficacy in an enzyme inhibition assay should not be used as the sole criterion to eliminate a given scaffold or compound, and additional studies should be undertaken concurrently before determining the usefulness of the inhibitor.
The unusually high potency and long duration of action of BoNT/ A, coupled with the intracellular localization of LC/A impose severe constraints on the discovery of effective inhibitors of BoNT/A intoxication (Adler et al., 2014) . The above may account for the finding that no SMIs examined to date have been able to provide robust protection from BoNT/A-induced lethality. Thus, a single inhibitor targeting only one aspect of the complex mechanism of BoNT action may not be adequate to treat botulism (Simpson, 2013) . This realization has led to consideration of alternative strategies for treatment of botulism. Among the promising emergent candidates, two are especially noteworthy: 1) atoxic BoNT constructs (VazquezCintron et al., 2017) capable of intracellular delivery of a broad range of inhibitors (e.g., highly potent camelid antibodies that target the active site of the LC (Tremblay et al., 2010) ; 2) selective inhibitors for the deubiquitinating enzyme VCIP135/VCPIP1, which is largely responsible for the neuronal persistence of LC/A (Tsai et al., 2017) . It is envisioned that an effective strategy for future treatment of BoNT/A intoxication will consist of one or more SMIs and/or potent camelid antibodies delivered by recombinant atoxic BoNTs to effectively inhibit LC/A and deubiquitinase inhibitors to accelerate its degradation.
Conclusions
Owing to the potential use of BoNT as a bioterrorism/biowarfare agent, coupled with the difficulties in the medical management of outbreaks and the absence of a specific drug treatment, a post exposure BoNT therapeutic is clearly needed. Development of an SMI for LC/A has been hampered by a number of factors, including the extended binding pocket of the enzyme (Segelke et al., 2004; Zuniga et al., 2010; Kumaran et al., 2015) and the disparate results obtained from different biological assays. In this study, we found that in spite of the relatively low potency of ABS 252/143 in enzymatic assays, the compounds were effective in the more complex biological assays. Most importantly, ABS 252 was able to show significant protection in a TTD animal model. Moreover, the X-ray crystal structure of ABS 252/143 and related compounds provides insights for building onto the existing scaffold. ABS 252 represents one of the few SMIs against LC/A that shows efficacy across a variety of biological assays as well as significant activity in an in vivo TTD model. In addition, in silico modeling suggests that ABS 252 has desirable pharmaceutical properties and conforms to Lipinski's rule of five in terms of its molecular weight, logP, number of hydrogen bond donors and number of hydrogen bond acceptors (Leeson, 2012) . As such, it is a promising candidate for developing as a small molecule therapeutic against botulinum intoxication.
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